Future oncology (London, England) · 2025
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antonio Franco, Carbognin Luisa, Paris Ida, Di Leone Alba, Orlandi Armando, Marazzi Fabio, Mule Antonino, Belli Paolo, Rossi Alessandro, Magno Stefano, Palazzo Antonella, Masiello Valeria, Santoro Angela, Fuso Paola, Bria Emilio, D'Archi Sabatino, Scardina Lorenzo, Sanchez Alejandro Martin, Giannarelli Diana, Paternello Stefano, Garganese Giorgia, Scambia Giovanni, Tortora Giampaolo, Masetti Riccardo, Franceschini Gianluca, Fabi Alessandra
Аннотация
BACKGROUND: Neoadjuvant chemotherapy (NACT) improves oncologic and cosmetic outcomes in breast cancer (BC), yet recurrence remains a concern. This study identifies factors associated with recurrence at 3 and 5 years in BC patients receiving NACT.
METHODS: A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.
RESULTS: Lower 5-year EFS was linked to axillary staging (cN, p < 0.001), molecular subtype (p < 0.001), surgery type (p = 0.030), and post-surgical nodal status (ypN, p = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.
CONCLUSION: Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.
METHODS: A retrospective analysis of 933 stage I - III BC patients (2014-2021) evaluated event-free survival (EFS) predictors using multivariate analyses.
RESULTS: Lower 5-year EFS was linked to axillary staging (cN, p < 0.001), molecular subtype (p < 0.001), surgery type (p = 0.030), and post-surgical nodal status (ypN, p = 0.005). High recurrence risk was observed with aggressive tumor biology, advanced disease, and residual nodal burden, while favorable responses correlated with better outcomes.
CONCLUSION: Biological and clinical factors guide post-NACT strategies to reduce recurrence in high-risk BC patients.